(Reuters) - Swiss drugmaker Novartis AG (>> Novartis) will buy U.S. gene therapy company AveXis Inc (>> AveXis Inc) for $8.7 billion in cash, the companies said on Monday.
(Reuters) - Swiss drugmaker Novartis will buy U.S. gene therapy company AveXis Inc for $8.7 billion in cash, the companies said on Monday.
The $218-per-share offer represents a premium of 88 percent to AveXis' Friday close.
(Reporting by Kanishka Singh in Bengaluru; Editing by Gopakumar Warrier)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 98.12 CHF | +0.12% | -7.43% | 31.23B | ||
| 85.53 CHF | +1.19% | -0.66% | 203B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
AVEXIS INC 
